RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
Clayton AH, Portman DJ, Kingsberg SA, et al.
The Journal of Sexual Medicine, 2020 · n = 627
Key finding
Bremelanotide significantly increased sexual desire scores (p<0.001) with 25% of women reporting much improved or very much improved vs 17% placebo.
Summary
Phase 3 double-blind RCT evaluating bremelanotide 1.75mg subcutaneous injection in premenopausal women with acquired HSDD. Primary endpoint was change in desire domain score.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
Skin Hyperpigmentation with Melanocortin-4 Receptor Agonists: Predictors and Prevention
The Journal of Sexual Medicine · 2020 · Human Pilot